Botulinum toxin injections to reduce adiposity: Possibility, or fat chance?

Medical Hypotheses

Volumn 67, Issue 5, 2006, Pages 1086-1089

  Lim, Erle C H ^a,b   Seet, Raymond C S ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; SIBUTRAMINE; SNARE PROTEIN; TETRAHYDROLIPSTATIN;

ARTICLE; BODY IMAGE; CLOSTRIDIUM BOTULINUM; DENERVATION; DIET; DRUG BINDING; DRUG MECHANISM; DRUG MEGADOSE; ENDOCYTOSIS; EXERCISE; HUMAN; INJECTION SITE REACTION; INSULIN RESISTANCE; LIPID STORAGE; LIPOATROPHY; LIPOLYSIS; LIPOSUCTION; METABOLIC SYNDROME X; MUSCLE WEAKNESS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; SELF CONCEPT; SUBCUTANEOUS FAT; SYMPATHETIC TONE;

ADIPOSE TISSUE; ANIMALS; BOTULINUM TOXINS; CLOSTRIDIUM BOTULINUM; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; INJECTIONS; OBESITY; RATS; VAGOTOMY;

EID: 33748077462     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.03.035     Document Type: Article

References (30)

1. Prentice A.M. The emerging epidemic of obesity in developing countries. Int J Epidemiol 35 (2006) 93-99
2. Khaitan L., and Smith C.D. Obesity in the United States: is there a quick fix? Pros and cons of bariatric surgery from the adult perspective. Curr Gastroenterol Rep 7 (2005) 451-454
3. Bray G.A. Medical consequences of obesity. J Clin Endocrinol Metab 89 (2004) 2583-2589
4. Villareal D.T., Apovian C.M., Kushner R.F., and Klein S. American society for nutrition; NAASO, the obesity society. Obesity in older adults: technical review and position statement of the American Society for Nutrition and NAASO. The Obesity Society. Obes Res 13 (2005) 1849-1863
5. Carr D., and Friedman M.A. Is obesity stigmatizing? Body weight, perceived discrimination, and psychological well-being in the United States. J Health Soc Behav 46 (2005) 244-259
6. Strychar I. Diet in the management of weight loss. CMAJ 174 (2006) 56-63
7. Poirier P., and Despres J.P. Exercise in weight management of obesity. Cardiol Clin 19 (2001) 459-470
8. Leone J.E., Sedory E.J., and Gray K.A. Recognition and treatment of muscle dysmorphia and related body image disorders. J Athl Train 40 (2005) 352-359
9. Flageul G., Elbaz J.S., and Karcenty B. [Complications of plastic surgery of the abdomen]. Ann Chir Plast Esthet 44 (1999) 497-505
10. Livingston E.H. Complications of bariatric surgery. Surg Clin North Am 85 4 (2005) 853-868 vii
11. Benotti P.N., Wood G.C., Rodriguez H., Carnevale N., and Liriano E. Perioperative outcomes and risk factors in gastric surgery for morbid obesity: A 9-year experience. Surgery 139 (2006) 340-346
12. Sidhaye A., and Cheskin L.J. Pharmacologic treatment of obesity. Adv Psychosom Med 27 (2006) 42-52
13. Matarasso A., and Pfeifer T.M. Plastic Surgery Educational Foundation DATA Committee Mesotherapy for body contouring. Plast Reconstr Surg 115 (2005) 1420-1424
14. Simpson L.L. Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol 44 (2004) 167-193
15. Dressler D., Saberi F.A., and Barbosa E.R. Botulinum toxin: mechanisms of action. Arq Neuropsiquiatr 63 (2005) 180-185
16. Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry 75 (2004) 951-957
17. Kreier F., Fliers E., Voshol P.J., et al. Selective parasympathetic innervation of subcutaneous and intra-abdominal fat - functional implications. J Clin Invest 110 (2002) 1243-1250
18. Singarachari A., and Krishamoorthy R.V. Increased fat degradation in the denervated muscle of frog. Indian J Physiol Pharmacol 20 (1976) 9-16
19. Kim S., and Matic D.B. The anatomy of temporal hollowing: the superficial temporal fat pad. J Craniofac Surg 16 (2005) 760-763
20. Balbo S.L., Mathias P.C., Bonfleur M.L., Alves H.F., Siroti F.J., Monteiro O.G., et al. Vagotomy reduces obesity in MSG-treated rats. Res Commun Mol Pathol Pharmacol 108 (2000) 291-296
21. Jones P.P., Davy K.P., Alexander S., and Seals D.R. Age-related increase in muscle sympathetic nerve activity is associated with abdominal adiposity. Am J Physiol 272 (1997) E976-E980
22. Lindmark S., Lonn L., Wiklund U., Tufvesson M., Olsson T., and Eriksson J.W. Dysregulation of the autonomic nervous system can be a link between visceral adiposity and insulin resistance. Obes Res 13 (2005) 717-728
23. Tugnoli V., Eleopra R., Montecucco C., and De Grandis D. The therapeutic use of botulinum toxin. Expert Opin Investig Drugs 6 (1997) 1383-1394
24. Molenaers G., Eyssen M., Desloovere K., Jonkers I., and De Cock P. A multilevel approach to botulinum toxin type A treatment of the (ilio)psoas in spasticity in cerebral palsy. Eur J Neurol 6 Suppl. 4 (1999) 59-62
25. Glogau R.G. Hyperhidrosis and botulinum toxin A: patient selection and techniques. Clin Dermatol 22 (2004) 45-52
26. Goodpaster B.H., Thaete F.L., Simoneau J.A., and Kelley D.E. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes 46 (1997) 1579-1585
27. Shirai K. Obesity as the core of the metabolic syndrome and the management of coronary heart disease. Curr Med Res Opin 20 (2004) 295-304
28. Wajchenberg B.L. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 21 (2000) 697-738
29. Busetto L. Visceral obesity and the metabolic syndrome: effects of weight loss. Nutr Metab Cardiovasc Dis 11 (2001) 195-204
30. Kopelman P.G. The effects of weight loss treatments on upper and lower body fat. Int J Obes Relat Metab Disord 21 (1997) 619-625